(Q37763493)

22 August 2017

1 reference

title

Role of allo-SCT for CML in 2010. (English)

1 reference

22 August 2017

N Venepalli

1

1 reference

22 August 2017

K Rezvani

series ordinal

2

1 reference

22 August 2017

S Mielke

series ordinal

3

1 reference

22 August 2017

B N Savani

series ordinal

4

1 reference

22 August 2017

language of work or name

English

0 references

publication date

7 June 2010

1 reference

Bone Marrow Transplantation

22 August 2017

1 reference

22 August 2017

45

1 reference

22 August 2017

11

1 reference

22 August 2017

1579-1586

1 reference

https://scigraph.springernature.com/pub.10.1038/bmt.2010.138

22 August 2017

0 references

cites work

First-line therapy for chronic myeloid leukemia: Past, present, and future

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

Imatinib therapy prior to myeloablative allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

Who with chronic myelogenous leukemia to transplant in the era of tyrosine kinase inhibitors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

Sibling versus unrelated donor allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia: refined HLA matching reveals more graft-versus-host disease but not less relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

Reduced-intensity allogeneic transplantation combined with imatinib mesylate for chronic myeloid leukemia in first chronic phase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multi

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

Reduced-intensity conditioning using TBI (8 Gy), fludarabine, cyclophosphamide and ATG in elderly CML patients provides excellent results especially when performed in the early course of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

The changing scene of allogeneic stem cell transplantation for chronic myeloid leukemia--a report from the German Registry covering the period from 1998 to 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

Comparison of myeloablative and nonmyeloablative hematopoietic stem cell transplantation for treatment of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

Comparison between reduced intensity and conventional myeloablative allogeneic stem-cell transplantation in patients with hematologic malignancies aged between 50 and 59 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

Lymphocyte recovery is a major determinant of outcome after matched unrelated myeloablative transplantation for myelogenous malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

Effect of missing killer-immunoglobulin-like receptor ligand in recipients undergoing HLA full matched, non-T-depleted sibling donor transplantation: a single institution experience of 151 Asian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

Transplantation from matched siblings using once-daily intravenous busulfan/fludarabine with thymoglobulin: a myeloablative regimen with low nonrelapse mortality in all but older patients with high-risk disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

Use of a reduced-intensity conditioning regimen for allogeneic transplantation in patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

Disease relapse after haematopoietic stem cell transplantation: risk factors and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

Current status and perspectives of tyrosine kinase inhibitor treatment in the posttransplant period in patients with chronic myelogenous leukemia (CML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

Graft-versus-host disease and graft-versus-leukemia after donor leukocyte infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

Current and emerging treatment options in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

Congestive heart failure is a rare event in patients receiving imatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

Cardiac morbidity in advanced chronic myelogenous leukaemia patients treated by successive allogeneic stem cell transplantation with busulphan/cyclophosphamide conditioning after imatinib mesylate administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

Management of drug toxicities in chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

Allogeneic stem-cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

7 January 2021

NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

7 January 2021

Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

7 January 2021

Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

7 January 2021

Comparable long-term survival after bone marrow versus peripheral blood progenitor cell transplantation from matched unrelated donors in children with hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

7 January 2021

No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

7 January 2021

Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

7 January 2021

Outcomes among 562 recipients of placental-blood transplants from unrelated donors

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

7 January 2021

Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

7 January 2021

Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

7 January 2021

Clinical outcomes and direct hospital costs of reduced-intensity allogeneic transplantation in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

7 January 2021

Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

7 January 2021

Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

7 January 2021

Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the F

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

7 January 2021

Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

7 January 2021

Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

7 January 2021

Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

7 January 2021

In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.138

7 January 2021

Identifiers

DOI

10.1038/BMT.2010.138

1 reference

22 August 2017

1 reference